Back to Search
Start Over
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2014 Feb; Vol. 55 (2), pp. 447-9. Date of Electronic Publication: 2013 Jun 24. - Publication Year :
- 2014
- Subjects :
- Antimetabolites, Antineoplastic administration & dosage
Antimetabolites, Antineoplastic adverse effects
Antimetabolites, Antineoplastic therapeutic use
Azacitidine administration & dosage
Azacitidine analysis
Azacitidine therapeutic use
Decitabine
Dose-Response Relationship, Drug
Humans
Injections, Subcutaneous
Male
Middle Aged
Primary Myelofibrosis complications
Risk Factors
Sweet Syndrome chemically induced
Sweet Syndrome complications
Treatment Outcome
Azacitidine adverse effects
Azacitidine analogs & derivatives
Primary Myelofibrosis drug therapy
Sweet Syndrome prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 55
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Report
- Accession number :
- 23647061
- Full Text :
- https://doi.org/10.3109/10428194.2013.802315